Women’s Health - 5EU Analysis and Market Forecasts
Summary
The Women’s Health medical devices market encompasses treatments for conditions that are particular to the adult female anatomy. This includes abnormal uterine conditions, such as menorrhagia and uterine fibroids, as well as pelvic disorders such as female stress urinary incontinence. Moreover, there is a sub-segment of the female population that no longer desire to become pregnant, and seek permanent solutions to avoid conception.
In recent years, minimally invasive techniques and technologies have been developed to treat these conditions as alternatives to conventional surgery; these technologies are expected to see increased adoption in the coming years due to increased physician and patient awareness as well as an increasing number of women who are proactively seeking treatment for these embarrassing, and sometimes debilitating, conditions. However, recent lawsuits related to safety issues with some of these devices that are receiving widespread media attention, particularly in the urinary incontinence sling market, have caused some women to be skeptical of these newer technologies.
The technologies covered in this report include global endometrial devices, endometrial resection devices, uterine fibroid embolization agents, female sterilization devices, and female urinary incontinence slings. The women’s health market is determined for the five major European markets (5EU): France, Germany, Italy, Spain, and the UK. The report provides insights into the competitive landscape, the marketed and pipeline products, the current and emerging players and market analysis of the different device segments within the women’s health market in the 5EU. The report also provides insight into the unmet needs and an understanding of physician perceptions of the market. This report is built using data and information sourced from secondary sources and primary research interviews with leading gynecologists, urogynecologists, interventional radiologists, and general surgeons, with in-house analysis conducted by GlobalData’s team of industry experts.
*This is an on-demand report and will be delivered within 4 working days (excluding weekends) of the purchase.
Highlights
Key Questions Answered
- What is the current and future women’s health market outlook in the 5EU? What trends are affecting these markets?
- Which are the key, high growth markets that manufacturers should expand into? Which markets are growing the fastest, and what are the top-selling products in each segment?
- What are the unmet needs with women’s health devices currently on the market? How will emerging technologies fulfill these unmet needs?
- What clinical factors and technical specifications influence a physician to use one type of device over another? What is physician perception and market outlook for women’s health devices?
- What are the challenges and complications that have hindered widespread adoption of newer technologies?
- With developing the next-generation of devices, what aspects of the technology are device manufacturers focused on optimizing? How will new entrants impact the 5EU women’s health market?
Scope
- Overview of women’s health, including anatomy, epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines and modalities.
- Annualized total women’s health market revenue from 2011-2021 including adoption patterns in the 5EU.
- Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement and regulatory considerations, and implications for the women’s health market.
- Pipeline analysis: Comprehensive data split across different stages of development, including a discussion of emerging trends and women’s health devices in development.
- Analysis of the current and future market competition in the 5EU women’s health market. Insightful review of the key industry drivers, opportunities, barriers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
- “What Physicians Think” quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. In this report you will understand the perceptions of leading gynecologists, urogynecologists, interventional radiologists, and general surgeons from around the world. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.
Summary
The Women’s Health medical devices market encompasses treatments for conditions that are particular to the adult female anatomy. This includes abnormal uterine conditions, such as menorrhagia and uterine fibroids, as well as pelvic disorders such as female stress urinary incontinence. Moreover, there is a sub-segment of the female population that no longer desire to become pregnant, and seek permanent solutions to avoid conception.
In recent years, minimally invasive techniques and technologies have been developed to treat these conditions as alternatives to conventional surgery; these technologies are expected to see increased adoption in the coming years due to increased physician and patient awareness as well as an increasing number of women who are proactively seeking treatment for these embarrassing, and sometimes debilitating, conditions. However, recent lawsuits related to safety issues with some of these devices that are receiving widespread media attention, particularly in the urinary incontinence sling market, have caused some women to be skeptical of these newer technologies.
The technologies covered in this report include global endometrial devices, endometrial resection devices, uterine fibroid embolization agents, female sterilization devices, and female urinary incontinence slings. The women’s health market is determined for the five major European markets (5EU): France, Germany, Italy, Spain, and the UK. The report provides insights into the competitive landscape, the marketed and pipeline products, the current and emerging players and market analysis of the different device segments within the women’s health market in the 5EU. The report also provides insight into the unmet needs and an understanding of physician perceptions of the market. This report is built using data and information sourced from secondary sources and primary research interviews with leading gynecologists, urogynecologists, interventional radiologists, and general surgeons, with in-house analysis conducted by GlobalData’s team of industry experts.
*This is an on-demand report and will be delivered within 4 working days (excluding weekends) of the purchase.
Highlights
Key Questions Answered
- What is the current and future women’s health market outlook in the 5EU? What trends are affecting these markets?
- Which are the key, high growth markets that manufacturers should expand into? Which markets are growing the fastest, and what are the top-selling products in each segment?
- What are the unmet needs with women’s health devices currently on the market? How will emerging technologies fulfill these unmet needs?
- What clinical factors and technical specifications influence a physician to use one type of device over another? What is physician perception and market outlook for women’s health devices?
- What are the challenges and complications that have hindered widespread adoption of newer technologies?
- With developing the next-generation of devices, what aspects of the technology are device manufacturers focused on optimizing? How will new entrants impact the 5EU women’s health market?
Scope
- Overview of women’s health, including anatomy, epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines and modalities.
- Annualized total women’s health market revenue from 2011-2021 including adoption patterns in the 5EU.
- Key topics covered include strategic competitor assessment, market characterization, identification of unmet needs, reimbursement and regulatory considerations, and implications for the women’s health market.
- Pipeline analysis: Comprehensive data split across different stages of development, including a discussion of emerging trends and women’s health devices in development.
- Analysis of the current and future market competition in the 5EU women’s health market. Insightful review of the key industry drivers, opportunities, barriers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
- “What Physicians Think” quotes provide a unique insight into how healthcare professionals are reacting to events within the industry, and what their responses could mean for industry strategists. In this report you will understand the perceptions of leading gynecologists, urogynecologists, interventional radiologists, and general surgeons from around the world. This information is essential for all strategic decision makers in every organization allowing them to act on high quality information.
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Industry Overview
3.1 Overview
3.1.1 Anatomy
3.2 Indications
3.2.1 Overview
3.2.2 Abnormal Uterine Conditions
3.2.3 Female Urinary Incontinence
3.3 Clinical Presentation
3.3.1 Abnormal Uterine Conditions
3.3.2 Female Urinary Incontinence
3.4 Market Segmentation
3.5 Market Access
3.5.1 Purchasing Decisions
3.6 Influence of Clinical Trials
3.7 Adoption
3.8 Regulation
3.8.1 5EU
3.9 Reimbursement
3.9.1 5EU
3.10 Procedure Trends
3.10.1 By Region
3.11 Regulatory Issues/Recalls
3.11.1 Hologic Discontinues Manufacturing, Marketing, and Sales of Adiana
3.11.2 Recall of Numerous Transvaginal Mesh Products
3.12 M&As, Key Partnerships
3.12.1 Bayer Health Acquires Conceptus for $1.1 Billion
3.12.2 Boston Scientific Acquires IoGyn for $65m
3.13 Economic Impact
3.13.1 Indirect Costs
3.13.2 Direct Costs
4 Unmet Needs
4.1 Overview
4.2 Endometrial Ablation/Resection Devices
4.2.1 Better Fluid Management
4.2.2 Improved Imaging Guidance
4.2.3 Regulating Depth of Ablation
4.3 Uterine Fibroid Embolization Agents
4.3.1 Addressing Fibroid Recurrence
4.3.2 Assessing Effect on Fertility
4.3.3 Preventing Ovarian Failure
4.4 Female Sterilization Devices
4.4.1 Accelerated Scar Tissue Formation
4.4.2 Lack of Reversibility
4.4.3 Preventing Micro-insert Migration
4.4.4 Preventing Perforation
4.4.5 Trocar Size Reduction
4.5 Female Urinary Incontinence Slings
4.5.1 Anatomical Adaptation
4.5.2 Single-Incision Slings
5 Market Opportunity Analysis
5.1 Overview
5.2 Endometrial Ablation/Resection Devices
5.2.1 Targeted Fibroid Ablation
5.3 Uterine Fibroid Embolization Agents
5.3.1 Novel Agents
5.4 Female Sterilization Devices
5.4.1 Raising Patient Awareness
5.4.2 Rapid Transcervical Sterilization
5.5 Female Urinary Incontinence Slings
5.5.1 Materials and Coatings
5.5.2 European and APAC Markets
6 Market Drivers and Barriers
6.1 Endometrial Ablation/Resection
6.1.1 Driver: Patient Preference for Minimally Invasive Treatments
6.1.2 Driver: Growing Procedure Volume
6.1.3 Barrier: High Device and Procedure Cost
6.1.4 Substitute: Hysterectomy
6.1.5 Substitute: Intrauterine Devices
6.2 Uterine Fibroid Embolization Agents
6.2.1 Driver: Increasing Prevalence of Uterine Fibroids
6.2.2 Driver: Improving Imaging Capabilities
6.2.3 Barrier: Lack of Patient Awareness
6.2.4 Substitute: MRI-guided Focused Ultrasound
6.2.5 Substitute: Myomectomy
6.3 Female Sterilization Devices
6.3.1 Driver: Growing Female Population using Modern Contraception
6.3.2 Driver: Increasing Adoption of Transcervical Sterilization
6.3.3 Barrier: Patient Preference for Reversible Contraception
6.3.4 Substitute: Traditional Contraception
6.4 Female Urinary Incontinence Slings
6.4.1 Driver: Growing Treatment Rates and Use of Surgery
6.4.2 Barrier: Highly Litigious US Market
6.4.3 Substitute: Surgical Repair
6.4.4 Substitute: Pelvic Floor Electrical Stimulation
7 Competitive Assessment
7.1 Overview
7.2 Classification Based on Features
7.2.1 Endometrial Ablation Devices
7.2.2 Endometrial Resection Devices
7.2.3 Uterine Fibroid Embolization Agents
7.2.4 Female Sterilization Devices
7.2.5 Female Urinary Incontinence Slings
7.3 Key Product Profiles
7.3.1 Endometrial Ablation Devices
7.3.2 Endometrial Resection Devices
7.3.3 Uterine Fibroid Embolization Agents
7.3.4 Female Sterilization Devices
7.3.5 Female Urinary Incontinence Slings
8 Pipeline Assessment
8.1 Overview
8.2 Key Product Profiles
8.2.1 Endometrial Ablation Devices
8.2.2 Uterine Fibroid Embolization Agents
8.2.3 Female Sterilization Devices
8.2.4 Female Urinary Incontinence Slings
9 Clinical Trials to Watch
9.1 Overview
9.2 Minerva Pivotal Study to Evaluate Safety and Efficacy of the Aurora Endometrial Ablation System Compared to Hysteroscopic Rollerball Ablation
9.3 Post Market Study of Single Incision Sling Versus Transobturator Sling for Stress Urinary Incontinence (Solyx)
9.4 Safety & Effectiveness Study of Aegea Vapor System to Treat Excessive Uterine Bleeding
9.5 The European Study of Altis Single Incision Sling System for Female Stress Urinary Incontinence (EASY)
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 American Medical Systems
10.3.2 AngioDynamics
10.3.3 Bayer Healthcare (Bayer AG)
10.3.4 Boston Scientific
10.3.5 BTG
10.3.6 Coloplast
10.3.7 Cook Medical
10.3.8 CooperSurgical
10.3.9 C.R. Bard
10.3.10 Ethicon (Johnson & Johnson)
10.3.11 Femcare-Nikomed (Utah Medical Products)
10.3.12 Hologic
10.3.13 Karl Storz
10.3.14 Olympus
10.3.15 Richard Wolf
10.3.16 Stryker
11 Market Outlook
11.1 By Geography
11.1.1 By Region
11.1.2 By Country
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Report Methodology
12.3.1 Overview
12.3.2 Coverage
12.3.3 Secondary Research
12.4 Forecasting Methodology
12.5 Physicians and Specialists Included in This Study
12.6 Primary Research - Prescriber Survey
12.7 About the Authors
12.7.1 Analysts
12.7.2 Global Head of Healthcare
12.8 About GlobalData
12.9 Disclaimer
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Related Reports
3 Industry Overview
3.1 Overview
3.1.1 Anatomy
3.2 Indications
3.2.1 Overview
3.2.2 Abnormal Uterine Conditions
3.2.3 Female Urinary Incontinence
3.3 Clinical Presentation
3.3.1 Abnormal Uterine Conditions
3.3.2 Female Urinary Incontinence
3.4 Market Segmentation
3.5 Market Access
3.5.1 Purchasing Decisions
3.6 Influence of Clinical Trials
3.7 Adoption
3.8 Regulation
3.8.1 5EU
3.9 Reimbursement
3.9.1 5EU
3.10 Procedure Trends
3.10.1 By Region
3.11 Regulatory Issues/Recalls
3.11.1 Hologic Discontinues Manufacturing, Marketing, and Sales of Adiana
3.11.2 Recall of Numerous Transvaginal Mesh Products
3.12 M&As, Key Partnerships
3.12.1 Bayer Health Acquires Conceptus for $1.1 Billion
3.12.2 Boston Scientific Acquires IoGyn for $65m
3.13 Economic Impact
3.13.1 Indirect Costs
3.13.2 Direct Costs
4 Unmet Needs
4.1 Overview
4.2 Endometrial Ablation/Resection Devices
4.2.1 Better Fluid Management
4.2.2 Improved Imaging Guidance
4.2.3 Regulating Depth of Ablation
4.3 Uterine Fibroid Embolization Agents
4.3.1 Addressing Fibroid Recurrence
4.3.2 Assessing Effect on Fertility
4.3.3 Preventing Ovarian Failure
4.4 Female Sterilization Devices
4.4.1 Accelerated Scar Tissue Formation
4.4.2 Lack of Reversibility
4.4.3 Preventing Micro-insert Migration
4.4.4 Preventing Perforation
4.4.5 Trocar Size Reduction
4.5 Female Urinary Incontinence Slings
4.5.1 Anatomical Adaptation
4.5.2 Single-Incision Slings
5 Market Opportunity Analysis
5.1 Overview
5.2 Endometrial Ablation/Resection Devices
5.2.1 Targeted Fibroid Ablation
5.3 Uterine Fibroid Embolization Agents
5.3.1 Novel Agents
5.4 Female Sterilization Devices
5.4.1 Raising Patient Awareness
5.4.2 Rapid Transcervical Sterilization
5.5 Female Urinary Incontinence Slings
5.5.1 Materials and Coatings
5.5.2 European and APAC Markets
6 Market Drivers and Barriers
6.1 Endometrial Ablation/Resection
6.1.1 Driver: Patient Preference for Minimally Invasive Treatments
6.1.2 Driver: Growing Procedure Volume
6.1.3 Barrier: High Device and Procedure Cost
6.1.4 Substitute: Hysterectomy
6.1.5 Substitute: Intrauterine Devices
6.2 Uterine Fibroid Embolization Agents
6.2.1 Driver: Increasing Prevalence of Uterine Fibroids
6.2.2 Driver: Improving Imaging Capabilities
6.2.3 Barrier: Lack of Patient Awareness
6.2.4 Substitute: MRI-guided Focused Ultrasound
6.2.5 Substitute: Myomectomy
6.3 Female Sterilization Devices
6.3.1 Driver: Growing Female Population using Modern Contraception
6.3.2 Driver: Increasing Adoption of Transcervical Sterilization
6.3.3 Barrier: Patient Preference for Reversible Contraception
6.3.4 Substitute: Traditional Contraception
6.4 Female Urinary Incontinence Slings
6.4.1 Driver: Growing Treatment Rates and Use of Surgery
6.4.2 Barrier: Highly Litigious US Market
6.4.3 Substitute: Surgical Repair
6.4.4 Substitute: Pelvic Floor Electrical Stimulation
7 Competitive Assessment
7.1 Overview
7.2 Classification Based on Features
7.2.1 Endometrial Ablation Devices
7.2.2 Endometrial Resection Devices
7.2.3 Uterine Fibroid Embolization Agents
7.2.4 Female Sterilization Devices
7.2.5 Female Urinary Incontinence Slings
7.3 Key Product Profiles
7.3.1 Endometrial Ablation Devices
7.3.2 Endometrial Resection Devices
7.3.3 Uterine Fibroid Embolization Agents
7.3.4 Female Sterilization Devices
7.3.5 Female Urinary Incontinence Slings
8 Pipeline Assessment
8.1 Overview
8.2 Key Product Profiles
8.2.1 Endometrial Ablation Devices
8.2.2 Uterine Fibroid Embolization Agents
8.2.3 Female Sterilization Devices
8.2.4 Female Urinary Incontinence Slings
9 Clinical Trials to Watch
9.1 Overview
9.2 Minerva Pivotal Study to Evaluate Safety and Efficacy of the Aurora Endometrial Ablation System Compared to Hysteroscopic Rollerball Ablation
9.3 Post Market Study of Single Incision Sling Versus Transobturator Sling for Stress Urinary Incontinence (Solyx)
9.4 Safety & Effectiveness Study of Aegea Vapor System to Treat Excessive Uterine Bleeding
9.5 The European Study of Altis Single Incision Sling System for Female Stress Urinary Incontinence (EASY)
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 American Medical Systems
10.3.2 AngioDynamics
10.3.3 Bayer Healthcare (Bayer AG)
10.3.4 Boston Scientific
10.3.5 BTG
10.3.6 Coloplast
10.3.7 Cook Medical
10.3.8 CooperSurgical
10.3.9 C.R. Bard
10.3.10 Ethicon (Johnson & Johnson)
10.3.11 Femcare-Nikomed (Utah Medical Products)
10.3.12 Hologic
10.3.13 Karl Storz
10.3.14 Olympus
10.3.15 Richard Wolf
10.3.16 Stryker
11 Market Outlook
11.1 By Geography
11.1.1 By Region
11.1.2 By Country
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Report Methodology
12.3.1 Overview
12.3.2 Coverage
12.3.3 Secondary Research
12.4 Forecasting Methodology
12.5 Physicians and Specialists Included in This Study
12.6 Primary Research - Prescriber Survey
12.7 About the Authors
12.7.1 Analysts
12.7.2 Global Head of Healthcare
12.8 About GlobalData
12.9 Disclaimer
Research Methodology
SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.
PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.
MARKET ENGINEERING
The market engineering phase involves analysing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.
REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.